Choosing between aspirin or P2Y12 monotherapy after short course of DAPT - 26/11/20
Doi : 10.1016/j.ahj.2020.09.003
Toshiki Kuno, MD, PhD a, ⁎ 
, Hiroki Ueyama, MD a, Hisato Takagi, MD, PhD b, Sripal Bangalore, MD, MHA c
, Hiroki Ueyama, MD a, Hisato Takagi, MD, PhD b, Sripal Bangalore, MD, MHA c a Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, New York, NY
b Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan
c Division of Cardiovascular Medicine, New York University Grossman School of Medicine, New York, NY
⁎Reprint requests: Toshiki Kuno, MD, PhD, FESC, FSCAI, Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth Israel, First Ave, 16th St, New York, NY 10003.FSCAI, Department of Medicine, Icahn School of Medicine at Mount Sinai, Mount Sinai Beth IsraelFirst Ave, 16th StNew YorkNY10003
Le texte complet de cet article est disponible en PDF.
| ☆ | Disclosure: Dr Bangalore is an advisory board member for Abbott Vascular, Biotronik, Amgen, Pfizer, and Reata. Remaining authors have nothing to disclose. |
| ☆☆ | Funding sources: none. |
© 2020
Elsevier Inc. Tous droits réservés.
Vol 230
P. 100 - décembre 2020 Retour au numéro
Article précédent
- Aspirin versus P2Y12 inhibitor–based monotherapy after percutaneous coronary intervention
- Rahul Choudhary, Vimla Kumari
- Letter to the editor: Discontinuation rates of warfarin versus direct acting oral anticoagulants in clinical practice
- Haris Khan, Moghees Hanif, Muhammad Asad Khan, Eushaa Mirza
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?